The introduction of Retatrutide in the UK is sparking significant anticipation within the obesity community. This innovative dual agonist – targeting both GLP-1 and GIP – suggests a remarkably new approach to addressing weight challenges. As of now , options have been limited for many, and Retatrutide represents a promising prospect for people